Rectal Adenocarcinoma Clinical Trial
Official title:
A Phase I/II Study of Nintedanib and Capecitabine in Refractory Metastatic Colorectal Cancer
Verified date | July 2021 |
Source | Roswell Park Cancer Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase I/II trial studies the side effects and best dose of nintedanib when given together with capecitabine and to see how well they work in treating patients with colorectal cancer that has not responded to previous treatment (refractory) and has spread to other places in the body (metastatic). Nintedanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It may also block the growth of new blood vessels necessary for tumor growth. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nintedanib with capecitabine may be a better treatment for colorectal cancer.
Status | Completed |
Enrollment | 42 |
Est. completion date | May 18, 2021 |
Est. primary completion date | November 1, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 - Hemoglobin >= 9 g/dL - Absolute neutrophil count >= 1500/mm^3 - Platelet count >= 100,000/mm^3 - Creatinine =< 1.5 upper limit of normal (ULN) AND creatinine clearance (CrCl) > 50 mL/min by Cockcroft-Gault equation - Males = (140 -age (yrs) (body weight (kg)/(72) (serum creatinine) (mg/dL) - Females = 0.85 * (140-age (yrs) (body weight (kg)/(72)(serum creatinine (mg/dL) - Bilirubin < ULN - Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 1.5 ULN if without liver metastases - AST/ALT =< 2.5 x ULN if with liver metastases - Coagulation parameters: international normalized ratio (INR) =< 2, prothrombin time (PT) and partial thromboplastin time (PTT) < 1.5 X institutional ULN - Have measurable disease per RECIST 1.1 criteria - Histologically or cytologically proven adenocarcinoma of the colon or rectum - Prior progression following a fluoropyrimidine-based therapy and progression following or intolerance to irinotecan and oxaliplatin, as well as anti-epidermal growth factor receptor (EGFR) therapy (e.g., panitumumab or cetuximab) for rat sarcoma viral oncogene homolog (RAS) wild-type patients - Ability to swallow and retain oral medication - Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry and for three months following completion of therapy; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately - Participant or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure Exclusion Criteria: - Prior treatment with nintedanib - Prior treatment with regorafenib - Major injuries or surgery within the 4 weeks prior to initiation of therapy with incomplete wound healing or planned surgery during the on-study treatment period - Uncontrolled hypertension: systolic blood pressure >= 160, diastolic blood pressure >= 90 - Urine protein/creatinine ratio >= 1.0 - History of clinically significant hemorrhagic or thrombotic event within the past 6 months, not including uncomplicated catheter-associated venous thrombosis; patients on anti-coagulation are not permitted to be on any oral formulations (warfarin, rivaroxaban, dabigatran, etc.) due to concern for drug-drug interaction - Unstable angina, symptomatic congestive heart failure or cardiac arrhythmia requiring anti-arrhythmic therapy (beta-blockers, calcium channel blockers and digoxin are allowed) - History of cerebrovascular or myocardial ischemia within 6 months of initiation - Known inherited predisposition to bleeding or thrombosis - Known active or chronic hepatitis B or C or human immunodeficiency virus (HIV) - Untreated brain metastases - History of second primary malignancy diagnosed within 3 years prior to enrollment, excluding: - In-situ cervical carcinoma - Superficial bladder cancer - Non-melanoma skin cancer - Stage I breast cancer - Low grade (Gleason =< 6) localized prostate cancer - Any additional malignancy which has been in clinical remission for at least 1 year - Pregnant or nursing female participants - Unwilling or unable to follow protocol requirements - Any condition which in the Investigator's opinion deems the participant an unsuitable candidate to receive study drug - Received an investigational agent within 4 weeks prior to enrollment - PHASE I: History of intolerance to capecitabine at doses =< 1000 mg/m^2 BID, as defined by documented >= grade 3 hand-foot syndrome, documented severe diarrhea requiring hospitalization, or other documented severe adverse events (AEs) attributable to capecitabine - PHASE II: History of intolerance to capecitabine at doses below 1000 mg/m^2 BID, as defined by documented >= grade 3 hand-foot syndrome; documented severe diarrhea requiring hospitalization; or other documented severe AEs attributable to capecitabine |
Country | Name | City | State |
---|---|---|---|
United States | Roswell Park Cancer Institute | Buffalo | New York |
United States | City of Hope Comprehensive Cancer Center | Duarte | California |
Lead Sponsor | Collaborator |
---|---|
Roswell Park Cancer Institute | Boehringer Ingelheim, National Cancer Institute (NCI), National Comprehensive Cancer Network |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To Examine the DLT | The recommended Phase II dose is of the Nintedanib and Capecitabine combination is defined as the dose level that causes dose limiting toxicities (DLTs) in = 1 out of 6 patients at highest dose level below the maximally administered dose.
Capecitabine is fixed dose at 2000 mg/m2; while Nintedanib is evaluated at 150mg (dose level 1) and 200 mg (dose level 2). |
At least 21 days. | |
Primary | Progression Free Survival (PFS) Rate, Defined as the Proportion of Patients Who Survive Without Disease Progression Via the RECIST Version 1.1 (Phase II) | Progressive disease is defined as at least a 20% increase in the sum of diameters of target lesions (the sum must also demonstrate an absolute increase of at least 5 mm) or the appearance of new lesions.
Will be summarized using standard Kaplan-Meier methods. |
At 18 weeks | |
Secondary | Median PFS (Phase II) | Progressive disease is defined as at least a 20% increase in the sum of diameters of target lesions (the sum must also demonstrate an absolute increase of at least 5 mm) or the appearance of new lesions. Estimates of median PFS will be obtained with corresponding 90% confidence intervals. | Up to 2 years | |
Secondary | Median OS (Phase II) | Overall survival is defined as time from date of subject enrollment to the date of death due to any cause. Estimates of median OS will be obtained with corresponding 90% confidence intervals. | From the date of enrollment to the time of death, assessed up to 2 years | |
Secondary | Objective Response Rate | Overall Response is defined as Complete Response: Disappearance of all target lesions and any lymph nodes must have a reduction in short axis to < 10 mm; or Partial Response: At least a 30% decrease in the sum of diameters of target lesions; or Stable Disease: Neither sufficient shrinkage to qualify for partial response, nor sufficient increase to qualify for progressive disease. | After every 3 cycles (9 weeks) of therapy. | |
Secondary | Aggregate Rates of Adverse Events Measured by CTCAE Version 4.0 (Phase II) | Number of Participants with Adverse Events, Graded According to the CTEP NCI Common Terminology Criteria for Adverse Events (CTCAE Version 4.0). | Up to 30 days after the last dose of study drug |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05081024 -
Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer
|
||
Not yet recruiting |
NCT04090450 -
Optimisation of Radiotherapy in Rectal Cancer (ORREC)
|
||
Recruiting |
NCT06050447 -
Factors Affecting the Results of Treatment of Patients With Colorectal Cancer
|
||
Terminated |
NCT02233595 -
Evaluation of Rectal Cancer Treatment Response Using PET/MRI
|
||
Completed |
NCT02935309 -
Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma
|
Phase 1 | |
Terminated |
NCT01887509 -
Evaluation of Rectal Tumor Margin Using Confocal Endomicroscopy and Comparison to Histopathology
|
N/A | |
Recruiting |
NCT05746195 -
Optimization of Adaptive Text Messages for Cancer Survivors (OATS II)
|
N/A | |
Active, not recruiting |
NCT03365882 -
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
|
Phase 2 | |
Completed |
NCT02314182 -
GRECCAR 8: Primary Tumor Resection in Rectal Cancer With Unresectable Metastasis
|
Phase 3 | |
Recruiting |
NCT04441580 -
Assessing the Additional Neoplasia Yield of Computer-aided Colonoscopy in a Screening Setting
|
N/A | |
Terminated |
NCT03527784 -
Prestoma-Trial for Parastomal Hernia Prevention
|
N/A | |
Completed |
NCT00855946 -
Proteomic Approach Using Matrix-assisted Laser Desorption/Ionization Tandem Time-of-flight (MALDI-TOF/TOF) of Tumor Response in Rectal Carcinoma After Radiochemotherapy
|
N/A | |
Recruiting |
NCT06328361 -
Nordic ORgan Preservation Pilot Approach Nonrandomised Single-Arm Trial for Non-Operative Management of Rectal Cancer
|
N/A | |
Recruiting |
NCT02107105 -
Evaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal Cancer
|
||
Terminated |
NCT03300544 -
Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03436563 -
M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04814784 -
Role of Neoadjuvent Radiotherapy in Locally Advanced Cancer Rectum
|
||
Recruiting |
NCT05482516 -
Evaluating Novel Therapies in ctDNA Positive GI Cancers
|
Phase 3 | |
Completed |
NCT02368886 -
Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02688712 -
ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer
|
Phase 2 |